Blood Test Could Detect Parkinson’s Disease Before Symptoms Appear
Researchers have identified blood biomarkers that may enable detection of Parkinson’s disease up to 20 years before symptoms.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Disease States |
Researchers have identified blood biomarkers that may enable detection of Parkinson’s disease up to 20 years before symptoms.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Lung Cancer |
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Read MorePosted by CLP Edit Staff | Feb 17, 2026 | Library Preparation Systems Flow |
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
Read MorePosted by CLP Edit Staff | Feb 11, 2026 | Dementias & Alzheimer’s, Diagnostic Technologies, Lab Management |
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer’s disease in symptomatic patients aged 55 and older.
Read MorePosted by CLP Edit Staff | Feb 10, 2026 | Molecular Diagnostic Analyzers |
BillionToOne has launched Northstar PGx and Northstar Select CH, two liquid biopsy add-on tests for advanced solid tumor therapy selection, enabling pharmacogenomic insights and clonal hematopoiesis detection from a single blood draw.
Read More